Siemens Healthineers Juggles Radiopharmacy Expansion and Diagnostics Pain Ahead of J.P. Morgan Forum

Siemens Healthineers stock down 22% after Q2 miss, guidance cut; Diagnostics weak but Imaging good. Market eyes China issues, radiopharmacy bet at forum.

Siemens Healthineers will take centre stage at the J.P. Morgan European Healthcare Forum in London tomorrow, but the backdrop is anything but celebratory. The stock has shed roughly 22% since the start of the year, closing at €35.11 on Tuesday, and the company is still nursing the wounds from a second-quarter earnings miss that forced a guidance cut. Yet even as investors nurse their losses, management is ploughing £26 million into a new radiopharmacy in Dunstable, UK — a bet on the kind of high-margin, high-tech imaging that underpins the group’s longer-term growth story.

The Q2 numbers, released on 7 May, painted a picture of a business moving in two very different directions. Imaging, the group’s largest division, posted comparable growth of 6.1% and a fat adjusted EBIT margin of 22.4%. Precision Therapy managed 4.7% growth with a 13.3% margin. Diagnostics, however, was the black sheep: revenue shrank 6.5%, hammered by structural market changes in China, and its adjusted EBIT margin limped in at just 0.9%. Group revenue slid to €5.68 billion, while adjusted earnings per share also edged lower.

That divergence forced a cautious reset. Siemens Healthineers now expects comparable revenue growth of 4.5% to 5.0% for fiscal 2026, down from the previous 5% to 6% range. Adjusted earnings per share are seen at €2.20 to €2.30, with the upper end trimmed from €2.40. The profit warning explains a good chunk of the stock’s steep descent: the 200-day moving average sits at €41.50, still more than 15% above Tuesday’s close, while the 52-week high of €49.86 is a distant 30% away.

The London forum will not feature any new financial releases — the company has not disclosed speakers or an agenda — but investors are likely to press for details on how sustainable the strength in Imaging and Precision Therapy really is, and when Diagnostics might hit the bottom in China. The next scheduled data point is the Q3 report on 31 July.

Technically, however, there are flickers of life. After tumbling to a May low, the stock has clawed back nearly 7%. It is now trading within sniffing distance of the 50-day moving average at €35.38. A clean break above that level would deliver a strong technical signal — the gap is currently less than 1% — and could mark the end of what has been a long, painful stretch.

In the meantime, the Dunstable investment underscores the group’s commitment to radiopharmaceuticals, a field that is becoming increasingly central to precision oncology. The new facility will produce eight times as much as previous models, reinforcing the supply of PET radiopharmaceuticals. It is the kind of specialised infrastructure that makes Siemens Healthineers indispensable to clinical excellence centres, much like the University Medical Center Hamburg-Eppendorf, which recently opted for its Photon-Counting CT systems.

Yet headwinds persist beyond the Diagnostics slump. The rise of GLP-1 weight-loss drugs poses a long-term question about diagnostic demand, and investor sentiment remains brittle. Against that fractious market, management has been quietly reinforcing its regional leadership: Nalan Abdullaho?lu took the helm for Turkey this week.

With the stock down roughly 23% over the past twelve months, much of the bad news is arguably already priced in. The combination of a potential technical breakout near the 50-day MA, fresh capacity in radiopharmacy, and the visibility from the J.P. Morgan event could give the bulls the narrative they need — provided the diagnostics story shows any sign of turning.